A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study

Rong Jiang¹
 Cheng Wu²
 Bigyan Pudasaini¹
 Lan Wang¹
 Qin-Hua Zhao¹
 Rui Zhang¹
 Wen-Hui Wu¹
 Ping Yuan¹
 Zhi-Cheng Jing¹
 Jin-Ming Liu¹

¹Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, ²Department of Health Statistics, Second Military Medical University, Shanghai, People's Republic of China

Background: Severe pulmonary hypertension (PH) resulting from a chronic lung disease (CLD) (severe CLD-PH) requires more aggressive treatment due to its increased mortality compared with mild PH. Therefore, we developed a Doppler echocardiography scoring index (ESI) to predict severe CLD-PH.

Methods: A derivation cohort of 107 patients with CLD who underwent echocardiography was classified into two groups, the normal/mild PH group and the severe PH group, based on the right heart catheterization. Meanwhile, we designed the ESI by multivariate logistic regression to validate the predicted outcomes. The ESI was calculated using the following formula: $ESI = ESI_{RVDT} + ESI_{PASP} + ESI_{PAD} - ESI_{TAPSE}$. Additionally, the ESI was weighted by +2 points for right ventricular end-diastolic transverse dimension ≥ 3.8 cm or pulmonary artery diameter ≥ 2.7 cm, +3 points for systolic pulmonary artery pressure (PASP) ≥ 61 mmHg, and -3 points for tricuspid annular plane systolic excursion ≥ 1.65 cm.

Results: In the derivation cohort, PASP ≥ 61 mmHg estimated by echocardiography exhibited 80.4% sensitivity and 84.3% specificity with area under receiver-operating characteristic curve of 0.823 (95% CI: 0.797–0.942, $P < 0.0001$). Compared with PASP, ESI ≥ 1.0 exhibited 91.1% sensitivity and 80.4% specificity, resulting in a net improvement in model performance with a change in the *c*-statistic from 0.823 to 0.937 and an integrated discrimination improvement of 11.3% (95% CI: 4.5%–18.2%, $P = 0.001$). The ESI was applied to the validation cohort, resulting in 84.2% sensitivity and 81.3% specificity with 82.9% accuracy.

Conclusion: The ESI showed high capacity for predicting severe CLD-PH, further implying the value of noninvasive examinations in clinic.

Keywords: pulmonary hypertension, echocardiography, hemodynamics, right heart catheterization, chronic lung disease

Introduction

Pulmonary hypertension (PH) is a common complication of a chronic lung disease (CLD) and is associated with increased mortality.^{1,2} PH often progresses to right heart failure (RHF), with initial compensatory right ventricle (RV) hypertrophy becoming overwhelmed by increasing pulmonary artery pressure (PAP). According to the updated conference consensus,^{2,3} CLD is classified into three groups: without PH (mean PAP [mPAP] < 25 mmHg), with PH (mPAP ≥ 25 mmHg), and with severe PH (mPAP ≥ 35 mmHg or $25 \text{ mmHg} < \text{mPAP} < 35 \text{ mmHg}$ with cardiac index $< 2.0 \text{ L/min/m}^2$ or pulmonary vascular resistance [PVR] > 6 Wood units).

Correspondence: Jin-Ming Liu;
 Zhi-Cheng Jing
 Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Yangpu District, Shanghai 200433, People's Republic of China
 Email jinningliu2013@126.com;
 jingzhicheng@vip.163.com

However, the severe PH group includes only a minority of patients with CLD who are suspected of having extensive general vascular remodeling accompanying the parenchymal disease that develops independently from pulmonary functional impairment and who have a poor prognosis. The detection of severe PH is important because it can provide the prognostic information to warrant more aggressive respiratory support and interventional cardiovascular procedures.

Right heart catheterization (RHC) is the gold standard for the diagnosis of severe PH because this method provides the hemodynamic information that defines this disease. Nevertheless, RHC is not routinely and repeatedly performed at initial diagnosis of PH and follow-up, especially in the People's Republic of China, where performance of RHC is limited by its invasiveness and high expenses. As a PH-screening tool, systolic PAP (PASP) can be estimated by measuring the peak tricuspid regurgitation velocity (TRV) on echocardiography, which continues to be recommended for early screening and as an assessment tool in patients with pulmonary arterial hypertension (PAH). However, in spite of its widespread use, the accuracy and reproducibility of echocardiography in predicting PASP have recently been questioned.⁴⁻⁹

The recently updated European Society of Cardiology (ESC) and European Respiratory Society guidelines on PH recommend testing for additional PH signs by assessing pulmonary artery diameter (PAd) and RV enlargement in addition to PASP.¹⁰ Whether a novel comprehensive echocardiography scoring index (ESI) derived from additional PH signs and PASP could improve the value of echocardiography for predicting severe PH was unknown.

Since patients with CLD accompanied by severe PH have a much poorer prognosis, this population attracts clinicians' attention, particularly because early and adequate treatment is needed to improve patient prognosis. Furthermore, it remains undetermined whether the assessment of a comprehensive ESI is beneficial for predicting severe PH. In the current study, we aimed to analyze the value of a comprehensive ESI for predicting severe PH in patients with CLD.

Materials and methods

Ethics

This study was conducted in accordance with the amended Declaration of Helsinki. The Local Institutional Ethics Committee of Shanghai Pulmonary Hospital approved the protocol (K08-015C), and written informed consent was obtained from all the patients in the validation cohort.

Study design

The retrospective derivation cohort and the prospective validation cohort were obtained from the Cardio-Pulmonary Circulation Center of Shanghai Pulmonary Hospital, which is the largest referral center for the diagnosis and treatment of PH in Shanghai, People's Republic of China.¹¹ For the derivation cohort, all consecutive patients with CLD hospitalized between January 2012 and December 2014 who were suspected of PH were included for model derivation. The validation cohort included a similar population recruited between January 2015 and July 2015 for model verification.

Inclusion and exclusion criteria

The patient inclusion criteria were as follows: 1) suspected PH associated with CLD;¹² 2) diagnosis of CLD confirmed by experienced specialists according to the appropriate guidelines;^{13,14} and 3) performance of RHC and Doppler echocardiography at a clinically stable stage during optimal medical therapy.

Patients were excluded for the following reasons: 1) diagnosis of other types of PH as per the NICE criteria;¹² 2) lack of RHC or echocardiography at a clinically stable stage; or 3) comorbidity of pulmonary embolism, severe left heart disease, and so on.

Procedures

A comprehensive set of quantitative echocardiography parameters was measured at rest (Vivid7 Dimension; GE Vingmed Ultrasound AS, Horten, Norway). The protocol and reference limits were in accordance with the current guidelines.¹⁵ Right ventricular end-diastolic transverse dimension (RVEDTD), right ventricular end-diastolic longitudinal dimension (RVEDLD), right atrial transverse dimension (RATD), right atrial longitudinal dimension (RALD), and end-systolic-stage eccentricity index (ENDSEI) were measured to indicate the presence or absence of right heart enlargement.¹⁵ PASP was measured by TRV with right atrium pressure (RAP) estimated by inferior cava diameter and inspiratory collapse.¹⁵ The PAd was also measured.¹⁵ RV function was assessed by measuring the tricuspid annular plane systolic excursion (TAPSE).¹⁵ Left ventricular ejection fraction was measured using M-mode in the parasternal long-axis view.

RHC was performed as described previously.¹⁶ The baseline hemodynamic variables evaluated included mPAP, RAP, pulmonary artery wedge pressure (PAWP), cardiac output (CO), cardiac index, and PVR.

All patients underwent RHC and echocardiography within 7 days at a clinically stable stage. Echocardiography was performed by two cardiologists (RJ and Q-HZ) who were blinded to all patients' medical history and RHC results. Similarly, the doctors who performed RHC were also blinded to the echocardiography results.

Statistical analysis

Continuous variables are described as the mean $\pm$ SD and median (interquartile range) for normally distributed variables and skewed distributed variables, respectively. Categorical variables are expressed as percentages. Pearson correlation coefficients for PASP between RHC and echocardiography (abbreviated as $PASP_{RHC}$ and $PASP_{ECHO}$, respectively) were calculated.

All echocardiography parameters were used to model the probability of having severe PH by means of binary logistic regression.¹⁷ A stepwise selection procedure was used to find independent predictors of severe PH with p-to-enter of ≤ 0.10 and p-to-remove of ≥ 0.15 . Variables assigned based on multiples of their rounded β -coefficients from the refitted model were used to define an ESI. All patients were classified into either the normal/PH group or the severe PH group. The receiver-operating characteristic (ROC) method was used to assess the ability of echocardiography variables and ESI to predict severe PH. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.

To verify the ESI's diagnostic ability, we conducted an internal and prospective validation. Landis and Koch¹⁸ defined kappa values of 0.00–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement. CIs were calculated with the adjusted percentile bootstrap method (n=10,000 replicates).

In all univariate analyses, $P \leq 0.05$ was considered statistically significant. All statistical methods were performed using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.04 software (GraphPad Software, Inc., San Diego, CA, USA).

Results

Derivation cohort

A total of 369 patients with CLD and suspected PH were admitted to our center between January 2012 and December 2014, of whom 107 underwent echocardiography ≤ 7 days before RHC (mean 3.3 ± 1.3 days before RHC; Figure 1).

Figure 1 Flow diagram for the main derivation cohort. Of the 369 patients with CLD and suspected PH who were referred to the Cardio-Pulmonary Circulation Center of Shanghai Pulmonary Hospital within the study period, 107 met the inclusion criteria and were considered in the analysis.

Abbreviations: CLD, chronic lung disease; PH, pulmonary hypertension; RHC, right heart catheterization; DE, Doppler echocardiography.

Fifty-six patients with severe PH and 51 patients with normal/PH with a median age of 62.0 (54.0, 67.5) years and consisting of 63.8% men were included. A small proportion of patients had significant comorbidities, such as systemic hypertension (19.0%), diabetes mellitus (3.9%), coronary heart disease (4.8%), arrhythmia (9.5%), and hyperlipidemia (2.9%) (Table 1). There were no significant differences in demographic characteristics, diagnostic classification, World Health Organization function class (WHO-FC), comorbidities, or pulmonary function test results between the groups (Table 1).

The $PASP_{ECHO}$ was measured at a clinically stable stage in 86.9% of all patients, which included 80.4% of the normal/PH group and 92.8% of the severe PH group. There was a moderately strong correlation between $PASP_{ECHO}$ and both $PASP_{RHC}$ and $mPAP_{RHC}$ ($r=0.665$ and $r=0.650$, both $P < 0.001$). Compared with the normal/PH group, the severe PH group showed significant abnormalities in the variables of echocardiography and RHC (all $P < 0.001$) (Table 1).

Multivariate analyses were performed to construct the ESI. Age, RATD, RALD, RVEDLD, and ENDSEI were excluded due to nonsignificant results by multivariate analysis, despite achieving statistical significance by univariate analysis. Stepwise logistic regression analysis revealed four variables that were independently significant: RVEDTD, PASP, PAD, and TAPSE. The formula for ESI

Table 1 Demographic characteristics, pulmonary function test results, hemodynamics, and echocardiography parameters of patients with normal/PH vs severe PH

Variable	Normal/PH (n=51)	Severe PH (n=56)	P-value
Age (years)	64.0 (57.5, 70.5)	61.0 (48.0, 67.8)	0.059
Men	30 (66.7%)	37 (61.7%)	0.638
BSA (m ²)	1.6±0.2	1.6±0.2	0.543
Diagnosis			
COPD	35 (68.6%)	40 (71.4%)	0.753
Interstitial lung disease	4 (7.8%)	6 (10.7%)	0.612
Other diseases with mixed restrictive and obstructive pattern			
Combined pulmonary fibrosis and emphysema	1 (2.0%)	1 (1.8%)	0.947
Lobectomy pulmonalis	3 (5.9%)	1 (1.8%)	0.267
Chest deformity	1 (2.0%)	1 (1.8%)	0.947
Lung destruction due to tuberculosis	3 (5.9%)	2 (3.6%)	0.573
Bronchiectasis	1 (2.0%)	3 (5.4%)	0.357
Pneumoconiosis	1 (2.0%)	0 (1.7%)	0.295
Sleep-disordered breathing	1 (2.0%)	2 (3.6%)	0.616
Alveolar hypoventilation disorders	1 (2.0%)	0	0.295
Comorbidities			
Systemic hypertension	10 (22.2%)	10 (16.7%)	0.616
Diabetes mellitus	3 (6.7%)	1 (1.7%)	0.311
Coronary heart disease	4 (8.9%)	1 (1.7%)	0.162
Malignant tumor	0	1 (1.7%)	0.386
Arrhythmia	6 (13.3%)	4 (6.7%)	0.320
Hyperlipidemia	3 (6.7%)	0	0.076
Previous cerebral infarction	0	1 (1.7%)	0.386
Pulmonary function test			
FEV ₁ % predicted	48.8±23.3	48.5±21.0	0.309
FVC % predicted	67.5±25.4	62.0±20.7	0.664
FEV ₁ /FVC % predicted	57.7±18.2	61.9±16.1	0.409
RV % predicted	178.9±62.9	156.3±55.3	0.178
TLC % predicted	109.5±27.4	101.2±19.6	0.197
DLco % predicted	51.4±27.4	57.6±33.9	0.471
Hemodynamics			
mRAP (mmHg)	4.0 (2.0, 5.0)	7.0 (4.0, 9.0)	<0.001
mPAP (mmHg)	29.0 (24.5, 32.0)	47.0 (41.0, 57.5)	<0.001
PAWP (mmHg)	8.1±3.4	9.9±4.3	0.022
CO (L/min)	5.7 (4.3, 6.6)	4.7 (4.0, 5.7)	0.034
Cardiac index (L/min/m ²)	3.5±0.8	3.2±1.0	0.192
PVR (Wood units)	3.6 (2.4, 4.8)	7.9 (6.2, 10.2)	<0.001
Echocardiography			
LVEF (%)	69.1±7.6	71.3±9.3	0.186
RATD (cm)	4.0 (3.5, 4.7)	4.8 (3.2, 5.5)	<0.001
RALD (cm)	4.5 (3.9, 5.4)	5.2 (4.5, 6.0)	0.005
RVEDTD (cm)	3.5 (3.1, 3.9)	4.3 (3.8, 5.0)	<0.001
RVEDLD (cm)	5.8 (5.5, 6.7)	6.5 (5.8, 7.1)	0.011
PASP (mmHg)	47.4±11.6	76.0±21.9	<0.001
TAPSE (cm)	2.0±0.3	1.7±0.3	<0.001
PAd (cm)	2.4 (2.2, 2.7)	2.8 (2.6, 3.2)	<0.001
ENDSEI	1.0 (1.0, 1.1)	1.3 (1.1, 1.5)	<0.001
PASP – yes	41 (80.4%)	52 (92.9%)	0.057

Note: Data shown as mean ± SD, n (%) or median (quartile range).

Abbreviations: PH, pulmonary hypertension; BSA, body surface area; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; mRAP, mean right atrium pressure; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; LVEF, left ventricular ejection fraction; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; TAPSE, tricuspid annular plane systolic excursion; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index.

Table 2 Logistic regression analysis of echocardiography parameters associated with severe PH

Variable*	Univariate analysis		β -coefficient	Weighted scores	Multivariate analysis	
	OR (95% CI)	P-value			OR (95% CI)	P-value
RATD (cm)	5.249 (2.262, 12.389)	<0.001	–	–	–	–
RALD (cm)	4.491 (2.138, 11.418)	<0.001	–	–	–	–
RVEDTD (cm)	10.771 (4.311, 26.909)	<0.001	1.665	2 [†]	5.283 (1.368, 20.403)	0.016
RVEDLD (cm)	3.229 (1.426, 7.313)	0.005	–	–	–	–
PASP (mmHg)	23.688 (8.383, 66.940)	<0.001	2.981	3 [†]	19.710 (5.032, 77.206)	<0.001
PAd (cm)	6.889 (2.789, 17.015)	<0.001	1.941	2 [†]	6.963 (1.803, 26.893)	0.005
ENDSEI	16.593 (4.621, 59.581)	<0.001	–	–	–	–
TAPSE (cm)	0.168 (0.058, 0.488)	0.001	–2.864	–3 [†]	0.057 (0.010, 0.320)	0.001

Notes: *Variables were transformed into binary variables according to optimum cutoff values. [†]If RVEDTD ≥ 3.8 cm or PAd ≥ 2.7 cm, weighted score = +2; if PASP ≥ 61 mmHg, weighted score = +3; and if TAPSE ≥ 1.65 cm, weighted score = –3.

Abbreviations: PH, pulmonary hypertension; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index; TAPSE, tricuspid annular plane systolic excursion.

was derived from the β -coefficients in the final model (Table 2): $ESI = ESI_{RVEDTD} + ESI_{PASP} + ESI_{PAd} - ESI_{TAPSE}$.

Based on ROC analysis, PASP ≥ 61 mmHg displayed 80.4% sensitivity and 84.3% specificity with an area under ROC curve (AUC) of 0.823 (95% CI: 0.797–0.942, $P < 0.0001$). The other parameters, except for RVEDTD, did not seem to

have good sensitivity and specificity for predicting severe PH (Table 3). Compared with $PASP_{ECHO}$, the ESI resulted in a net improvement in model performance, with a change in the c -statistic from 0.823 to 0.937 (95% CI: 0.890–0.984, $P < 0.001$) and an integrated discrimination improvement of 11.3% (95% CI: 4.5%–18.2%, $P = 0.001$) (Figure 2).

Table 3 The distribution of echocardiography parameters and accuracy for discrimination

Variable	All subjects (n=107)	Normal/PH (n=51)	Severe PH (n=56)	P-value	Sensitivity (%)	Specificity (%)	Area under the curve (95% CI)
RATD (cm)							
<4.2	46 (43.0)	33 (64.7)	13 (23.2)	<0.001	0.768	0.647	0.707 (0.607, 0.807)
≥ 4.2	61 (57.0)	18 (35.3)	43 (76.8)				
RALD (cm)							
<4.8	52 (48.6)	35 (68.6)	17 (30.4)	0.008	0.696	0.686	0.650 (0.543, 0.756)
≥ 4.8	55 (51.4)	16 (31.4)	39 (69.6)				
RVEDTD (cm)							
<3.8	47 (43.9)	14 (27.5)	10 (17.9)	<0.001	0.821	0.725	0.801 (0.716, 0.886)
≥ 3.8	60 (56.1)	37 (72.5)	46 (82.1)				
RVEDLD (cm)							
<6.4	61 (57.0)	14 (27.5)	11 (19.6)	0.002	0.571	0.725	0.672 (0.569, 0.774)
≥ 6.4	46 (43.0)	37 (72.5)	45 (80.4)				
PASP (mmHg)							
<61	54 (50.5)	43 (84.3)	11 (19.6)	<0.001	0.804	0.843	0.869 (0.797, 0.942)
≥ 61	53 (49.5)	8 (15.7)	45 (80.4)				
PAd (cm)							
<2.7	57 (53.3)	39 (76.5)	18 (32.1)	<0.001	0.679	0.765	0.745 (0.675, 0.855)
≥ 2.7	50 (46.7)	12 (23.5)	38 (67.9)				
ENDSEI							
<1.05	48 (46.9)	35 (68.6)	13 (23.3)	<0.001	0.768	0.683	0.792 (0.706, 0.878)
≥ 1.05	59 (55.1)	16 (31.4)	43 (76.8)				
TAPSE (cm)							
<1.65	27 (25.2)	5 (9.8)	22 (39.3)	0.001	0.902	0.607	0.684 (0.584, 0.784)
≥ 1.65	80 (74.8)	46 (90.2)	34 (60.7)				

Note: Data shown as n (%).

Abbreviations: PH, pulmonary hypertension; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDLD, right ventricular end-diastolic longitudinal dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; ENDSEI, end-systolic-stage eccentricity index; TAPSE, tricuspid annular plane systolic excursion.

Figure 2 The receiver-operator characteristic curve is shown for PASP alone as determined by echocardiography variables and for ESI in predicting severe PH.

Abbreviations: PASP, pulmonary arterial systolic pressure; ESI, echocardiography scoring index; PH, pulmonary hypertension; AUC, area under the curve; DE, Doppler echocardiography.

Since severe PH should capture clinicians' attention due to its poor prognosis, to minimize the chance of overlooking a case of severe PH, we examined several alternate cutoff values of the ESI and determined the cutoff value that maximized sensitivity with the least compromise in specificity (Table S1). Therefore, we chose 1.0 as the optimal cutoff value for the ESI. With $ESI \geq 1.0$ as the definition of a model-predicted case of severe PH, the sensitivity, specificity, PPV, and NPV were 91.1%, 80.4%, 83.6%, and 89.1%, respectively.

Figure 3 shows representative echocardiography traces from two patients with CLD who were verified as having mild or severe PH on RHC.

Validation cohort

A total of 127 patients with CLD and suspected PH between Jan 2015 and Jul 2015 were admitted to our center, of whom 16 adult patients had normal/mild PH and 19 had severe PH. Clinical data are presented in Tables S2 and S3. A trend towards lower $PASP_{ECHO}$ or $PASP_{RHC}$ and mean RAP was seen in the validation cohort. The ESI was validated in the cohort with 84.2% sensitivity, 81.3% specificity, 84.2% PPV, 81.3% NPV, and 82.9% accuracy. The ESI showed precise and substantial kappa agreement (0.655, 95% CI: 0.370–0.884).

Discussion

We derived and validated a comprehensive ESI by combining additional PH signs and $PASP_{ECHO}$ for predicting severe

PH in patients with CLD. $ESI \geq 1.0$ displayed satisfactory sensitivity, specificity, PPV, NPV, and accuracy in predicting severe PH and is recommended to be applied in clinical practice due to its noninvasive nature and cost effectiveness.

Despite availability of targeted PH medication for PAH, no targeted medication is approved at the moment for PH in CLD and use of targeted drugs would be off-label. Compared with patients with CLD in the normal/PH group, patients in the severe PH group exhibited poorer prognosis and higher mortality.^{10,19} Therefore, it is important for clinicians to detect severe PH in patients earlier and to initiate adequate treatment in order to improve patient prognosis. RHC is the gold standard for measuring not only mPAP but also PAWP, cardiac index, CO, and PVR. RHC cannot be replaced by echocardiography. Nevertheless, RHC cannot be performed in every hospital, especially in the People's Republic of China. Sometimes, patients are not willing to undergo RHC during follow-up because of its invasiveness and cost. However, as a PH-screening tool, PASP can be estimated by measuring the peak TRV on echocardiography, which continues to be recommended for early screening and assessment in patients with idiopathic PAH, chronic thromboembolism-associated PH, or connective tissue disease-associated PAH.²⁰ However, PASP estimation is often inaccurate, especially in patients with CLD, and requires the presence of sufficient tricuspid regurgitation (TR), proper Doppler alignment, and optimal visualization of the regurgitant jet. Moreover, the absence of TR is not sufficient to exclude PH, and the TRV might be underestimated in patients with CLD who have hyperinflation of the lungs and marked respiratory variations in intrathoracic pressure.⁹ Even if a TR is observed, PAP_{ECHO} is often inaccurate and leads to both false-positive and false-negative diagnoses of PH,¹⁹ not to mention an inability to determine severe PH. Compared with $PASP_{RHC}$, $PASP_{ECHO}$ was found to be inaccurate in 52% of COPD cases, with a tendency to overestimate PAP.⁹ Indeed, 48% of patients were misclassified as having PH by echocardiography alone.^{9,21} In addition, some studies have identified a strong relationship between $mPAP_{ECHO}$ and $mPAP_{RHC}$.²² However, the diagnostic utility of $mPAP_{ECHO}$ for specific underlying etiologies, such as emphysema, has been questioned.²¹ In other studies,^{9,23} $PASP_{ECHO}$ predicted PH in patients with CLD with 76%–85% sensitivity, 17%–38% specificity, 56%–60% PPV, and 44%–60% NPV. Consequently, $PASP_{ECHO}$ and $mPAP_{ECHO}$ have not yet been adopted as stand-alone tools capable of accurately measuring pulmonary hemodynamics.

At present, this ESC guideline suggests grading the probability of PH based on TRV and additional prespecified

Figure 3 Representative echocardiographic images of RVEDTD, PASP, PAd, and tricuspid annular plane systolic excursion as well as the score calculation for two patients. Column **A** (top to bottom) shows $\uparrow$ RVEDTD and $\uparrow$ PASP (score = -1). Invasive hemodynamics: mPAP = 30 mmHg, PAWP = 11 mmHg, PVR = 6.0 Wood units, and cardiac index = 3.1 L/min/m². Column **B** shows $\uparrow$ RVEDTD, $\uparrow$ PASP, $\uparrow$ PAd, and $\downarrow$ TAPSE (score = 4). Invasive hemodynamics: mPAP = 39 mmHg, PAWP = 11 mmHg, PVR = 6.0 Wood units, and cardiac index = 3.35 L/min/m².

Abbreviations: RVEDTD, right ventricular end-diastolic transverse dimension; PASP, pulmonary arterial systolic pressure; PAd, pulmonary artery diameter; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; ESI, echocardiography scoring index.

echocardiographic variables that are suggestive of PH.¹⁰ Additional signs of PH such as RV dilation, eccentricity index, and PAd²⁴ have been reported to discern PAH with high sensitivity. Many years ago, several studies derived and validated equations using additional PH signs to estimate PVR or mPAP as confirmed by RHC in patients with PH.^{4,5,23} Prior studies have tried but failed to utilize acceleration time in the right ventricular outflow tract (RVOT) to measure PAP or predict PH in patients with CLD.^{25,26} Opatowsky et al reported that the RVOT velocity or RVOT velocity time integral has been proposed as a PVR prediction model^{5,8} for determining the severity of PH with the exception of PH due to CLD²⁴ or for estimating PAP in children with CLD.²⁷ However, the above-stated methods were slightly more cumbersome, and we favor simply measured variables to increase clinical utility.

In our research, we derived a novel comprehensive index by combining RVEDTD, PAd, and TAPSE in addition to

PASP_{ECHO}. This index has several advantages. First, the ESI's sensitivity and specificity are substantially higher than PASP_{ECHO}, with an increase in the *c*-statistic from 0.823 to 0.937. Second, the four variables are not cumbersome to measure and are easy to obtain. Third, the ESI is noninvasive, reliable, and easy to integrate into clinical practice, especially during follow-up.

D'Alto et al⁶ reported that echocardiography allows for accurate measurements of pulmonary circulation but with moderate precision by Bland–Altman analysis, which explains why the procedure is valid for population studies but cannot be used for the diagnosis of PH in individual patients. Because our research objective is to make a cutoff value to differentiate “severe PH” from “normal/PH” rather than replace gold criterion by new parameter, Bland–Altman analysis might not be suitable for our research. We calculated accuracy and precision in accordance with categorical

variable and kappa, respectively. In our study, there were no significant biases, and the ESI showed 82.9% accuracy in the validation cohort. However, the ESI had a kappa statistic of 0.655, indicating substantial but not high agreement. Our results are consistent with earlier reports and could help clinicians perform preliminary screening of patients with suspected severe PH.

Although the parameter for the discrimination of severe PH is an mPAP of 35 mmHg by RHC, the corresponding $PASP_{ECHO}$ of 61 mmHg derived from the sample seems very high. This is far greater than the calculated PASP of 53 mmHg⁷ or 54 mmHg²⁸ for an mPAP of 35 mmHg. This indicates that $PASP_{ECHO}$ was not sufficient for predicting PH in patients with CLD.

As we know, the severity of PH should not be judged by PAP but rather by clinical outcomes such as WHO-FC, hospitalization, RHF, up-titration of medications, transplantation, or mortality. However, our research was a diagnostic study that validated the capacity of a comprehensive echocardiography index for predicting severe PH in patients with CLD. In the future, our research would be strengthened by determining the predictive nature of the formula in clinical outcomes from the validation cohort. A formula that could predict clinical outcomes in this population would be more useful. We will further consider this problem when we have a large patient cohort that can be followed over time and will develop a formula based on those data.

Study limitations

This study has several limitations that need to be considered when interpreting the results. First, this was a single-center study, which may have patient selection bias because not all the patients with CLD had undergone RHC. However, patients admitted into our center came from all over People's Republic of China, which may reduce bias. Second, echocardiography and RHC were not conducted simultaneously; therefore, the delay between procedures could be considered a limitation of this study. However, the included patients received similar levels of support and treatment at the times of echocardiography and RHC, and there were no detectable differences in medications or fluid status between the two groups. All patients underwent RHC at a clinically stable stage, manifesting relief of respiratory failure and RHF. The number of days between echocardiography and RHC was also validated as insignificant by logistical regression. Importantly, the strength of the present study is the evaluation of these tests through actual application in clinical practice.

Conclusion

We present a simple clinical tool that helps to predict severe PH in patients with CLD. The integrated ESI combining additional PH signs and $PASP_{ECHO}$ improved the accuracy of predicting severe PH based on echocardiography. If patients with CLD have an ESI >1.0, they should receive clinicians' attention and should undergo RHC because they may have a high risk of severe PH and pulmonary vascular remodeling. Early diagnosis and treatment are crucial in this patient population.

Acknowledgment

This study was supported by the National Natural Science Foundation of China (81600032) and the YangFan Program of Shanghai Science and Technology Committee (15YF1409700).

Author contributions

Drs RJ, RZ, and J-ML contributed to the experimental design, study conduct, data analysis, and drafting and revising the manuscript. LW, Q-HZ, and PY contributed to the data collection and revising manuscript. BP, CW, W-HW, and Z-CJ contributed to the experimental design, interpretation of data, and revising the manuscript. All authors had full access to all study data and had final responsibility for the decision to submit for publication. All have reviewed the manuscript and approved the final version for submission. All the authors ensured that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Disclosure

Prof Z-CJ serves as a consultant and scientific advisor to Actelion, Bayer Schering, AstraZeneca, Pfizer, and United Therapeutics, in addition to being an investigator in trials sponsored by these companies. The other authors report no conflicts of interest in this work.

References

1. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. *Pediatrics*. 2008;121(2):317–325.
2. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. *J Am Coll Cardiol*. 2013;62(25 Suppl):D109–D116.
3. Hoeper MM, Andreas S, Bastian A, et al. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. *Int J Cardiol*. 2011;154 Suppl 1:S45–S53.
4. Robinson B, Ebeid M. A simple echocardiographic method to estimate pulmonary vascular resistance. *Am J Cardiol*. 2014;113(2):412.

5. Opatowsky AR, Clair M, Afilalo J, et al. A simple echocardiographic method to estimate pulmonary vascular resistance. *Am J Cardiol*. 2013; 112(6):873–882.
6. D'Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. *Int J Cardiol*. 2013;168(4):4058–4062.
7. Aduen JF, Castello R, Daniels JT, et al. Accuracy and precision of three echocardiographic methods for estimating mean pulmonary artery pressure. *Chest*. 2011;139(2):347–352.
8. Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound*. 2010;8:21.
9. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med*. 2003;167(5):735–740.
10. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016;37(1):67–119.
11. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. *Chest*. 2011;140(2):301–309.
12. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 Suppl): D34–D41.
13. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2013;187(4): 347–365.
14. Meyer KC, Raghu G, Baughman RP, et al; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. *Am J Respir Crit Care Med*. 2012;185(9):1004–1014.
15. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23(7):685–713; quiz 786–788.
16. Jiang R, Ai ZS, Jiang X, et al. Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. *Hypertens Res*. 2015;38(8):539–544.
17. Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. *Lancet*. 2002;360(9342):1287–1292.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33(1):159–174.
19. Barberà JA, Blanco I. Management of pulmonary hypertension in patients with chronic lung disease. *Curr Hypertens Rep*. 2015;17(8):62.
20. Pristera N, Musarra R, Schilz R, Hoit BD. The role of echocardiography in the evaluation of pulmonary arterial hypertension. *Echocardiography*. 2016;33(1):105–116.
21. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. *Eur Respir J*. 2007;30(5):914–921.
22. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *J Am Coll Cardiol*. 1985;6(2):359–365.
23. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. *Respir Med*. 2007;101(10): 2153–2159.
24. López-Candales A, Edelman K. Shape of the right ventricular outflow Doppler envelope and severity of pulmonary hypertension. *Eur Heart J Cardiovasc Imaging*. 2012;13(4):309–316.
25. Marchandise B, De Bruyne B, Delaunois L, Kremer R. Noninvasive prediction of pulmonary hypertension in chronic obstructive pulmonary disease by Doppler echocardiography. *Chest*. 1987;91(3):361–365.
26. Torbicki A, Skwarski K, Hawrylkiewicz I, Pasiński T, Miskiewicz Z, Zielinski J. Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. *Eur Respir J*. 1989;2(9):856–860.
27. Newth CJ, Gow RM, Rowe RD. The assessment of pulmonary arterial pressures in bronchopulmonary dysplasia by cardiac catheterization and M-mode echocardiography. *Pediatr Pulmonol*. 1985;1(1):58–62.
28. Chemla D, Castelain V, Provencher S, Humbert M, Simonneau G, Hervé P. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. *Chest*. 2009;135(3):760–768.

Supplementary materials

Table S1 Sensitivity, specificity, positive predictive values, and negative predictive values of the diagnostic index

Cutoff values	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Derivation cohort				
Cutoff =1.5	87.5	92.2	92.5	87.0
Cutoff =1.0	91.1	80.4	83.6	89.1
Validation cohort				
Cutoff =1.5	64.7	76.9	78.6	62.5
Cutoff =1.0	81.3	84.2	84.2	81.3

Abbreviations: PPV, positive predictive value; NPV, negative predictive value.

Table S2 Comparison of characteristics of patients of derivation cohort vs validation cohort

Variable	Derivation cohort (n=107)	Validation cohort (n=35)	P-value
Age (years)	63.0 (54.0, 70.0)	63.0 (56.5, 68.0)	0.998
Men (%)	67	21	0.458
BSA (m ²)	1.6 (0.2)	1.6 (0.2)	0.204
Diagnosis			
COPD	36 (80.0)	27 (90.0)	0.157
ILD	4 (8.9)	3 (10.0)	0.863
Bronchiectasia	10 (22.2)	8 (26.7)	0.962
Other pulmonary diseases with mixed restrictive and obstructive pattern			
CPFE	1 (2.2)	1 (3.3)	0.893
Lobectomy pulmonalis	4 (8.9)	0	0.229
Chest deformity	1 (2.2)	1 (6.7)	0.320
Emphysema and bullae	2 (4.4)	4 (13.3)	0.228
Lung destruction due to tuberculosis	3 (6.7)	1 (3.3)	0.286
Pneumoconiosis	1 (2.2)	0	0.452
Sleep-disordered breathing	1 (2.2)	0	0.356
Alveolar hypoventilation disorders	2 (4.4)	0	0.452
Comorbidities			
Systemic hypertension	20 (19.0)	7 (23.3)	0.493
Diabetes mellitus	4 (3.9)	2 (6.7)	0.490
Coronary heart disease	4 (4.8)	1 (3.3)	0.420
Malignant tumor	1 (1.0)	1 (3.3)	0.629
Arrhythmia	10 (9.5)	2 (6.7)	0.460
Hyperlipidemia	3 (2.9)	2 (6.7)	0.320
Previous cerebral infarction	1 (1.0)	0	0.596
Pulmonary function test			
FEV ₁ % predicted	32.8 (23.7, 60.4)	33.0 (20.0, 44.3)	0.201
FVC % predicted	53.0 (39.5, 63.3)	56.4 (43.9, 63.0)	0.406
FEV ₁ /FVC % predicted	55.2 (44.5, 69.0)	45.0 (39.7, 67.5)	0.067
RV % predicted	156.9 (106.3, 217.0)	196.4 (108.1, 304.0)	0.237
TLC % predicted	100.5 (80.8, 122.1)	107.2 (78.3, 135.4)	0.461
RV/TLC % predicted	67.2 (53.9, 78.1)	71.1 (51.0, 79.5)	0.681
DLco % predicted	48.9 (26.9, 64.2)	29.6 (23.5, 53.8)	0.128
DLco/VA % predicted	50.8 (27.2, 72.6)	35.4 (23.2, 66.8)	0.292

Note: Data shown as mean (SD) or median (quartile range).

Abbreviations: BSA, body surface area; ILD, interstitial lung disease; CPFE, combined pulmonary fibrosis and emphysema; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; VA, alveolar volume.

Table S3 Comparison of hemodynamics and echocardiography parameters of patients of derivation cohort vs validation cohort

Variable	Derivation cohort (n=107)	Validation cohort (n=35)	P-value
Hemodynamics			
mRAP (mmHg)	5.0 (3.0, 8.0)	3.0 (1.0, 5.0)	0.001
mPAP (mmHg)	36.0 (29.0, 48.0)	35.0 (28.5, 42.0)	0.169
PAWP (mmHg)	9.2 (3.8)	8.2 (5.3)	0.188
CO (L/min)	5.0 (4.2, 6.1)	5.0 (4.2, 6.5)	0.716
Cardiac index (L/min/m ²)	3.3 (0.9)	3.2 (0.8)	0.820
PVR (Wood units)	3.6 (3.5, 8.1)	5.0 (3.0, 7.3)	0.484
Echocardiography parameters			
Continuous variables			
LVEF (%)	70.0 (64.0, 77.0)	70.5 (62.0, 77.3)	0.186
RATD (cm)	4.4 (3.7, 5.3)	4.3 (3.7, 4.6)	0.256
RALD (cm)	4.8 (4.1, 5.7)	4.6 (4.2, 5.2)	0.274
RVEDTD (cm)	3.9 (3.3, 4.5)	3.7 (3.5, 4.2)	0.581
RVEDSD (cm)	6.2 (5.6, 6.8)	6.1 (5.7, 6.9)	0.971
PASP (mmHg)	60.0 (43.0, 76.0)	51.0 (35.0, 65.0)	0.009
TAPSE (cm)	1.8 (1.6, 2.0)	1.8 (1.6, 2.2)	0.940
PAd (cm)	2.6 (2.4, 2.9)	2.8 (2.5, 3.0)	0.103
ENDSEI	1.1 (1.0, 1.3)	1.1 (1.0, 1.3)	0.338
Categorical variables			
RH enlargement* – yes	81 (75.7%)	22 (73.3%)	0.792
PA dilation – yes	48 (44.9%)	17 (56.7%)	0.094
ENDSEI – yes	60 (56.1%)	15 (50.0%)	0.556
PASP – yes	93 (86.9%)	17 (56.7%)	<0.001

Notes: Data shown as mean (SD), median (25th, 75th percentiles) or n (%). *Include right atrium and right ventricle enlargement.

Abbreviations: mRAP, mean right atrium pressure; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; LVEF, left ventricular ejection fraction; RATD, right atrial transverse dimension; RALD, right atrial longitudinal dimension; RVEDTD, right ventricular end-diastolic transverse dimension; RVEDSD, right ventricular end-diastolic dimension; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; PAd, pulmonary arterial diameter; ENDSEI, end-systolic eccentricity index; RH, right heart; PA, pulmonary artery.

International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress